Lyell Immunopharma, Inc. (LYEL) ownership: Top institutional holder: ARCH Venture Management, LLC ($65.14M). Insider activity: Net Seller (2 buys, 18 sells). SEC EDGAR first-party data.
| Holder | Shares | Market Value | Reported |
|---|---|---|---|
| ARCH Venture Management, LLC | 3247162.00 | $65.14M | 2026-03-31 |
| MWG Caph Ltd | 1008116.00 | $31.03M | 2025-12-31 |
| GSK plc | 1512659.00 | $30.34M | 2026-03-31 |
| VANGUARD GROUP INC | 826430.00 | $25.44M | 2025-12-31 |
| Foresite Capital Management IV, LLC | 800399.00 | $16.06M | 2026-03-31 |
| Orland Properties Ltd | 754698.00 | $15.14M | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 718155.00 | $14.41M | 2026-03-31 |
| Almitas Capital LLC | 577807.00 | $11.59M | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-06-10 | |
| Sell | null | 2026-06-10 | |
| Sell | null | 2026-06-10 | |
| Sell | null | 2026-06-10 | |
| Sell | null | 2026-06-10 | |
| Sell | null | 2026-06-10 | |
| Sell | null | 2026-06-10 | |
| Sell | null | 2026-03-09 |
Back to LYEL overview · LYEL earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.